Huntington National Bank purchased a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in the third quarter, according to the company in its most recent filing with the SEC. The firm purchased 1,084 shares of the biotechnology company’s stock, valued at approximately $105,000.
Several other institutional investors and hedge funds also recently made changes to their positions in the company. BDO Wealth Advisors LLC acquired a new stake in shares of BioMarin Pharmaceutical during the 2nd quarter worth about $127,000. Allen Investment Management LLC acquired a new stake in shares of BioMarin Pharmaceutical in the second quarter worth approximately $203,000. Reilly Financial Advisors LLC acquired a new stake in shares of BioMarin Pharmaceutical in the second quarter worth approximately $254,000. Wedbush Securities Inc. acquired a new stake in shares of BioMarin Pharmaceutical in the second quarter worth approximately $262,000. Finally, Atria Investments LLC acquired a new stake in shares of BioMarin Pharmaceutical in the second quarter worth approximately $277,000.
In other news, Director Alan Lewis sold 4,200 shares of the business’s stock in a transaction on Tuesday, August 21st. The shares were sold at an average price of $100.09, for a total transaction of $420,378.00. Following the completion of the transaction, the director now owns 21,160 shares of the company’s stock, valued at $2,117,904.40. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Elaine J. Heron sold 1,000 shares of the business’s stock in a transaction on Wednesday, September 5th. The shares were sold at an average price of $96.94, for a total transaction of $96,940.00. Following the transaction, the director now directly owns 41,685 shares of the company’s stock, valued at approximately $4,040,943.90. The disclosure for this sale can be found here. In the last three months, insiders have sold 69,850 shares of company stock valued at $6,911,128. Corporate insiders own 1.90% of the company’s stock.
BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings data on Thursday, October 25th. The biotechnology company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.15. BioMarin Pharmaceutical had a negative net margin of 8.35% and a negative return on equity of 2.98%. The firm had revenue of $391.71 million during the quarter, compared to the consensus estimate of $369.43 million. Equities research analysts anticipate that BioMarin Pharmaceutical Inc. will post -0.14 earnings per share for the current year.
Several research firms recently commented on BMRN. Stifel Nicolaus raised their price target on shares of BioMarin Pharmaceutical from $102.00 to $109.00 and gave the company a “buy” rating in a report on Friday, August 3rd. JPMorgan Chase & Co. restated a “buy” rating and issued a $135.00 price target on shares of BioMarin Pharmaceutical in a report on Sunday, August 5th. Citigroup raised their price target on shares of BioMarin Pharmaceutical from $108.00 to $120.00 and gave the company a “buy” rating in a report on Thursday, August 9th. Canaccord Genuity lifted their price objective on shares of BioMarin Pharmaceutical from $105.00 to $113.00 and gave the company a “buy” rating in a research note on Tuesday, July 31st. Finally, Wedbush set a $120.00 price objective on shares of BioMarin Pharmaceutical and gave the company a “buy” rating in a research note on Thursday, September 13th. One analyst has rated the stock with a sell rating, four have given a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $117.00.
COPYRIGHT VIOLATION NOTICE: “Huntington National Bank Purchases Shares of 1,084 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)” was first published by BBNS and is owned by of BBNS. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://baseballnewssource.com/2018/11/16/huntington-national-bank-purchases-new-position-in-biomarin-pharmaceutical-inc-bmrn/2872839.html.
BioMarin Pharmaceutical Profile
BioMarin Pharmaceutical, Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome.
Featured Story: Fundamental Analysis and Individual Investors
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.